WASHINGTON--(BUSINESS WIRE)--Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for infectious diseases, today released new data showing its vaccine adjuvants boosting the protection of influenza vaccines in animal models. The Kineta adjuvant system controls influenza infection by enhancing the anti-viral cellular immune response and boosting the production of functional antibodies. Adjuvants are molecules added to a vaccine to improve the body’s vaccine immune response. They were discovered through Kineta’s proprietary AViid™ discovery platform, which is focused on the small molecules that activate the IRF-dependent immune pathways. The data were presented by Kineta’s Dr. Chelsea Olsen, Associate Director of Program Management and Virology, in an oral presentation at the World Vaccine Congress during the Influenza and Respiratory segment of the conference.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
